PHILADELPHIA, July 25, 2025 /PRNewswire/ -- Berger Montague PC, a national securities litigation law firm announces it is investigating potential securities fraud claims involving RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST), following the recent filing of a federal securities class action lawsuit.The lawsuit alleges that Defendants failed to disclose to investors that: (1) RxSight was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2 ...

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims against RxSight, Inc. for misleading statements regarding its business and financial performance during the specified Class Period [1][4]. Company Background - RxSight, Inc. is a commercial-stage medical technology company that specializes in the research, development, manufacturing, and marketing of light-adjustable intraocular lenses (LAL) used in cataract surgery [3]. Securities Fraud Claims - The class action complaint alleges that RxSight made materially false and misleading statements, failing to disclose declines in product sales and utilization, and overstating demand for its intraocular lens products [4]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [4]. Financial Performance - On July 9, 2025, RxSight reported significant declines in sales of its Light Delivery Device (LDD), usage of its light-adjustable intraocular lenses (LALs), and total revenue, leading to a reduction in its Full Year 2025 guidance by approximately $42.5 million [5]. - Following this disclosure, RxSight's stock price fell by $4.84 per share, or 37.8%, closing at $7.95 per share on July 9, 2025 [5].

Core Viewpoint - DJS Law Group is investigating claims against RxSight, Inc. for potential violations of securities laws related to misleading statements and undisclosed information impacting investors [1][2]. Investigation Details - The investigation centers on RxSight's financial performance, particularly the decline in sales of Light Delivery Devices (LDD) and total revenue [2]. - RxSight reported a significant drop in key metrics and lowered its full-year financial guidance, attributing the changes to "adoption challenges" leading to an "LDD stall" [2]. - Following the financial report, RxSight's shares plummeted by nearly 38% on the announcement day [2].

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its financial performance and customer demand [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to securities purchased between November 7, 2024, and July 8, 2025, during which investors are encouraged to participate before September 22, 2025 [2]. - The Schall Law Firm is representing investors and has not yet certified the class, meaning potential participants are not yet represented by an attorney [3]. Group 2: Allegations Against RxSight - The complaint alleges that RxSight faced "adoption challenges" leading to declining sales and utilization rates, and that the company overstated customer demand for its products [4]. - It is claimed that RxSight is unlikely to meet its financial guidance for fiscal year 2025, and that its public statements were materially misleading throughout the class period [4].

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025. SO WHAT: If you purchased RxSight securities during the Class P ...

Core Insights - RxSight, Inc. will report its financial results for Q2 2025 on August 7, 2025, after market close [1] - A conference call to discuss the results will take place at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Company Overview - RxSight, Inc. specializes in ophthalmic medical devices, focusing on customized vision solutions for patients post-cataract surgery [3] - The company offers the RxSight® Light Adjustable Lens system, which is the first and only intraocular lens technology that can be adjusted after surgery [3] - This technology allows doctors to provide tailored high-quality vision to patients following cataract procedures [3] Contact Information - Chief Financial Officer: Shelley B. Thunen, Email: sthunen@rxsight.com [4] - VP, Investor Relations: Oliver Moravcevic, Email: omoravcevic@rxsight.com [4]

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired RxSight securiti ...

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities during the specified class period [1][2]. Company Overview - RxSight, Inc. is a medical technology company based in Aliso Viejo, CA, specializing in light adjustable intraocular lenses (LAL) used in cataract surgery, with its system involving the Light Delivery Device (LDD) [2]. Legal Allegations - The lawsuit alleges that RxSight's management failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the sales stall to adoption challenges over recent quarters [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit, titled Makaveev v. RxSight, Inc., is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. Group 3: Financial Impact - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38% from $26.12 to $16.21 per share [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell another 38% from $12.79 to $7.95 per share [6].

Core Viewpoint - A securities class action lawsuit has been filed against RxSight, Inc. for failing to disclose significant operational challenges and misleading investors regarding the company's financial outlook [1][2]. Group 1: Allegations Against the Company - The lawsuit alleges that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is claimed that the company overstated the demand for its products, which contributed to an inability to meet previously issued financial guidance for fiscal year 2025 [2]. - The positive statements made by the company regarding its business operations and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Financial Impact - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in LDD sales, LAL utilization, and overall revenue [3]. - Following this announcement, the company's stock price dropped by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, with unusually heavy trading volume [3].